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Abstract
The pattern of patients admitted to internal medicine wards has dramatically changed in the last 20–30 years. 
Elderly people are now the most rapidly growing proportion of the patient population in the majority of 
Western countries, and aging seldom comes alone, often being accompanied by chronic diseases, comorbid-
ity, disability, frailty, and social isolation. Multiple diseases and multimorbidity inevitably lead to the use of 
multiple drugs, a condition known as polypharmacy. Over the last 20–30 years, problems related to aging, 
multimorbidity, and polypharmacy have become a prominent issue in global healthcare. This review discusses 
how internists might tackle these new challenges of the aging population. They are called to play a primary 
role in promoting a new, integrated, and comprehensive approach to the care of elderly people, which should 
incorporate age-related issues into routine clinical practice and decisions. The development of new approaches 
in the frame of undergraduate and postgraduate training and of clinical research is essential to improve and 
implement suitable strategies meant to evaluate and manage frail elderly patients with chronic diseases, comor-
bidity, and polypharmacy.
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Introduction
The pattern of patients admitted to internal medicine 
wards has dramatically changed in the last 20–30 years. 
The internist used to see patients mainly complain-
ing of illnesses affecting only one organ or apparatus 
[1]. They had been trained in medical school and 
during postgraduate specialization to acquire a broad 
knowledge and an holistic approach to diagnosis and 
treatment in order to effi ciently tackle the varied clini-
cal problems presented by relatively young patients 
usually suffering from a single disease [1–3]. This situ-
ation changed in the last part of the 20th century, when 
tremendous developments in health technology made 
it diffi cult for most internists to follow progress and 
become profi cient in the advances that marched at a 
fast and often overwhelming pace [2, 3]. This led to 
the birth or development of various subspecialties of 
internal medicine (such as cardiology, gastroentero-
logy, pulmonology, and others) that had tremendous 
impetus and increasing popularity in the community, 
and hence among healthcare planners. The growth 
and appeal of subspecialties was paralleled by a period 
of uncertainty about the role and mission of general 
internal medicine, and in many instances, hospital 
medical wards had to yield space to specialized units 
[4, 5]. What has dramatically altered this pattern in 
the last few years? The fact that the internist had to 
deal increasingly more with the management of elderly 
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people with multiple chronic diseases rather than with 
young people with single diseases. 
Population aging, chronic diseases, and 
multimorbidity
Elderly people are now the most rapidly growing part of 
the patient population worldwide, thanks to more focus 
on primary prevention of diseases and improvements in 
healthcare for the younger ill patient [6]. A century ago, 
one individual in 20 was aged 65 years or over, now 
one in six is, and by 2050 it is expected to be one in 
four. Individuals aged 80 years or more are the fastest 
growing section of the population and are expected to 
reach nearly 30% of the overall population in the richest 
nations by 2050 [7, 8]. 
The process of aging involves a continuum of changes 
in biological, functional, psychological, and social 
parameters that vary, depending on genetic factors, age-
related vulnerability, and differences in organ function 
and reserves. Table 1 summarizes the main age-related 
changes in organ and system functions [9–11]. 
Aging seldom comes alone: it is often accompanied 
by chronic (multiple) diseases, comorbidity, disabil-
ity, frailty, and social isolation [8, 10]. It is unusual 
for elderly patients to have only one disease affecting 
only one organ or apparatus [12–14]. Even though, for 
example, acute pneumonia may be the ultimate cause 
of hospital admission for an 80-year-old woman, she 
may very often also complain of, for instance, con-
comitant diabetes, heart failure, osteoporosis, anemia, 
and hypertension. Organ subspecialists sometimes 
fi nd it diffi cult to tackle all these different diseases, 
which are unlikely to be seen concomitantly in the 
younger patients they are usually accustomed to caring 
for [15–17]. Accordingly, the holistic approach of the 
internist to patient healthcare has become increasingly 
more important, and the role and visibility of internal 
medicine has been magnifi ed. 
Table 1 Main age-related changes in organ systems.
Organ system Effects of aging Prescribing implications
Body composition Progressive reduction in total body water and lean 
body mass
Increase in body fat
Cardiac and 
peripheral vascular 
system
Heart changes (stiffening, reduced muscle strength)
Reduction in the intrinsic heart rate
Atherosclerosis and loss of elasticity of vessel walls
Higher systolic arterial pressure
Increased impedance to left ventricular ejection
Left ventricular hypertrophy and interstitial fi brosis
Reduced response to postural changes
Increased heart rate
Central nervous 
system
Increased sensitivity
Decreased blood fl ow
Decline in receptors and pathways (fewer brain cells 
and connections)
Enhanced response to CNS agents
Slower mobility and voluntary motor activity
Delirium
Gastrointestinal Decreased secretion of hydrochloric acid and pepsin
Dysfunction in GI motility
Decreased GI blood fl ow
Reduction in liver volume and blood fl ow
Constipation
Reduced absorption and metabolism of several drugs
Immune system Decreased immunity to diseases
Greater susceptibility to infections
Increase in antibiotic use
Musculoskeletal Loss of muscle tissue
Osteoarthritis
Osteoporosis 
Increased use of analgesic and anti-infl ammatory 
drugs
Increased risk of falls and fractures
Renal Reduction of renal mass and blood fl ow
Decline in GFR
Prolonged effects of drugs poorly excreted by the 
kidney
Respiratory Vital capacity and FEV may decline with age
Increased rigidity of chest wall
Reduced thorax muscle strength and endurance
Loss of strength and endurance of lungs with some 
drugs
Sensory Visual impairment, thickening and yellowing of the 
lens of the eye
Hearing impairment, loss of sensitivity for 
high-frequency tones and of discrimination of 
similar pitches
Decline in the ability to taste and smell
Reduced adherence to drug therapies
CNS, central nervous system; FEV, forced expiratory volume; GFR, glomerular fi ltration rate; GI, gastrointestinal.
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Multimorbidity in the elderly has been estimated to 
range from 55 to 98% [13], and is highest in the very 
old, in women, and individuals belonging to low socio-
economic classes [13, 18]. Although multimorbidity 
often simply involves the co-occurrence of two or more 
diseases, the distribution, combination, and develop-
ment of different diseases (clustering) need to be better 
understood, as well as the mechanisms leading to the 
co-occurrence of diseases and the natural history of 
multimorbidity [13, 19]. In assessing these individu-
als, attention must be paid to genetic and biological 
factors, lifestyles, socioeconomic determinants, and 
how these factors interact to determine multimorbidity 
[13, 20–23].
The lack of well-designed clinical studies recruiting 
these patients limits the availability of evidence-based 
information on the effect of multiple drugs on such 
clinically relevant outcomes as functional and cognitive 
decline, quality of life, adverse events, and mortal-
ity [24–27]. Most clinical research projects in internal 
medicine still focus on the disease-oriented approach, 
which does not take account of the complexity and over-
lapping health and social problems of elderly patients 
[28, 29]. Despite these limitations, over the last few dec-
ades, many clinical care models and interventions have 
been developed and tested for patients with multimor-
bidity, especially in geriatric settings, and have been 
reviewed by Boult and colleagues [30].
Polypharmacy and medication-related 
problems in the elderly
The prescription and use of multiple drugs to deal with 
concomitant multiple diseases is known as polyphar-
macy [31–33]. Regardless of the defi nition, the high 
prevalence of polypharmacy with aging may lead to 
an increased risk of inappropriate drug use, under-use 
of effective treatments, medication errors, poor adher-
ence, drug–drug and drug–disease interactions and, 
most importantly, adverse drug reactions [34–39]. 
The latter are usually related to the established fact 
that elderly people are often frail and highly sensitive 
to pharmacotherapy, because of changes in pharma-
cokinetic and pharmacodynamic parameters [40, 41] 
(Tables 2 and 3) and impairment in many organ func-
tions (Table 1) [43].
Polypharmacy is an important risk factor for inap-
propriate medication prescribing [35, 39, 44], which is 
very frequent among elderly people [35, 45]. Certain 
drugs are considered inappropriate or potentially inap-
propriate in older patients not only because of the higher 
risk of intolerance related to adverse pharmacokinetics 
or pharmacodynamics or drug–disease interactions but 
also because they are prescribed at too high dosages or 
for too long [46]. A European study involving 900 con-
secutive elderly patients admitted to university teaching 
hospitals in six countries found that potentially inappro-
priate prescribing ranged from 22 to 77%, depending 
on the criteria used [47]. However, an understated 
aspect of inappropriate prescribing in elderly people is 
also the omission of medications known to be effective 
in patients with an adequate life expectancy and good 
quality of life, because of lack of knowledge and fear of 
adverse drug reactions, in addition to other irrational 
reasons [35–37, 48–50]. The OLDY (OLd people Drugs 
and dYsregulations) study found that more than 40% of 
elderly patients were ultimately undertreated for such 
frequent and severe clinical ailments as heart failure, 
myocardial infarction, atrial fi brillation, osteoporosis, 
pain, and depression [51]. Moreover, polypharmacy is 
often an adverse consequence of the so-called ‘prescrib-
ing cascade’, which involves the clinician’s failure to 
recognize a new medical event as an adverse drug reac-
tion [52, 53]. In this case, another drug is unnecessarily 
prescribed to treat the adverse event instead of with-
drawing the drug responsible, creating a vicious circle 
and adding further risks. 
Among hospitalized elderly patients, the prevalence of 
polypharmacy ranges from 20 to 60%, perhaps refl ecting 
different criteria in the selection of patients and collec-
tion of medication data [35, 54–57]. For instance, in the 
REPOSI (Registro Politerapie SIMI) study, a registry 
based on an Italian network of 38 internal medicine 
wards, 52% of patients aged 65 years or older were tak-
ing fi ve or more drugs at hospital admission. This had 
risen to 67% at discharge: the number of diseases, occur-
rence of an adverse event during hospitalization, length 
of hospital stay, and the presence of chronic diseases 
(such as hypertension, coronary artery disease, atrial 
fi brillation, heart failure, presence of chronic obstruc-
tive pulmonary disease, osteoporosis/osteoarthritis, and 
chronic renal failure) were predictors of polypharmacy 
at discharge [54].
Polypharmacy can also negatively infl uence medica-
tion adherence (compliance) [58–62]. Among elderly 
people, non-compliance has a prevalence of 25–75%, 
and the likelihood rises in proportion to the number of 
drugs and daily doses prescribed [58, 61, 62]. Poor adher-
ence often becomes more marked with age, in relation 
to problems such as the complexity of the therapeutic 
regimen, visual or hearing impairment, functional and 
cognitive deterioration, depression, disease burden, and 
social isolation [58, 60–63]. Therapeutic complexity, 
number of different prescribers, more visits to pharma-
cies and lower refi ll consolidation have been associated 
with poor adherence and early discontinuation of long-
term treatments. Differences in drug adherence may also 
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comorbidities can be implemented easily in younger 
adults, but has many limitations in older patients, because 
it fails to take into account age-related changes in phar-
macokinetics and pharmacodynamics, coexistence of 
other acute or chronic diseases, use of multiple drugs, 
risk of drug–drug or drug–disease interactions, cogni-
tive status, and disability [46, 78, 79]. The dosages and 
effects of medications, benefi cial or adverse, are defi -
nitely different in the elderly than in younger patients, 
the latter population being typically and almost exclu-
sively enrolled in randomized clinical trials designed for 
drug licensing. 
The evidence on which clinical guidelines are based 
usually stems from randomized clinical trials or meta-
analyses, which are often biased by the exclusion or 
under-representation of elderly people, especially those 
affected by multimorbidity and receiving polypharmacy 
[24, 80–84]. A recent analysis of patient enrollment in 
clinical trials for cancer drugs found only 20% and 9%, 
respectively, of patients older than 70 and 75 years, com-
pared with 46% and 31% for the whole cancer population 
in the USA [82]. Another study showed that despite 
the high prevalence of heart failure in older patients, 
more than 40% of clinical trials had one or more poorly 
justifi able exclusion criteria that limited the inclusion of 
elderly patients [84]. In most randomized clinical trials, 
sample size, duration, and co-prescribed drug therapies 
are often tailored to the target disease, and geriat-
ric problems, such as disability, cognitive impairment, 
multimorbidity, life expectancy, and socioeconomic dif-
fi culties, are seldom considered [24, 25, 27, 80].
These limitations make it diffi cult to extrapolate 
the results of clinical trials and the resulting guideline 
recommendations to older people. For instance, if a cli-
nician applies the relevant guidelines to a woman aged 
79 years with hypertension, type 2 diabetes mellitus, 
chronic obstructive pulmonary disease, osteoarthritis, 
and osteoporosis, the patient should be taking 19 daily 
be related to the days of week and the dosing regimen. 
For instance, failure to take a dose of a antihypertensive 
drug is more common at the weekend, and morn-
ing doses are more likely to be taken accurately than 
evening doses [64]. Non-adherence or poor adherence 
may result in progression of the disease, hospital admis-
sions, and a higher healthcare cost. One study showed 
that 11% of hospital admissions of elderly people aged 
65 years or older were the result of non-adherence and 
this reached 26% in those aged 75 years or more [65]. 
In elderly people, polypharmacy has been associ-
ated with many adverse clinical outcomes, such as drug 
interactions and adverse drug reactions, disability and 
cognitive impairment, falls and fractures, malnutrition, 
hospitalization and institutionalization, mortality, and 
rising healthcare costs [35, 37, 46, 66–76]. The increas-
ing risk of adverse drug reactions may be related either 
to direct adverse effects of one or more of the prescribed 
drugs or to pharmacological interactions among them. 
A European study found that 46% of 1,601 elderly 
patients from six countries had at least one potentially 
clinically signifi cant drug interaction [77]. The number 
of drugs taken is closely related to the risk of adverse 
drug reactions, independent of clinical diagnoses [74]. 
In addition, the risk of falling is positively associated 
with the number of drugs, irrespective of age and level 
of disability, particularly when elderly patients are tak-
ing benzodiazepines, diuretics, and anticholinergic 
agents [72].
Limitations of guidelines in elderly people
The decision to prescribe a drug is often based on a 
disease-oriented approach that stems from guideline 
recommendations for each single symptom, disease, 
or clinical problem [24, 25, 28]. This paradigm of 
care focused on a specifi c disease and closely related 
Table 3 Main age-related changes in pharmacodynamics.
Pharmacodynamic changesa Clinical implications
The impact of aging on drug sensitivity or tolerance varies 
with the drug and the response measured
The changes observed may result from alterations in 
drug–receptor interactions (e.g. change in the number 
and/or affi nity of receptors), changes in post-receptor 
signalling or impairment of homeostatic mechanisms
Age-related changes of clinical targets may affect the 
pharmacological response to a drug
Age-related pharmacodynamic changes in the CNS and 
cardiovascular system have received most attention
Increased sensitivity to benzodiazepines (e.g. sedation, confusion) with risk 
of falls and fractures 
Increased sensitivity to anticholinergic drug effects (e.g. agitation, confusion, 
delirium, postural hypotension)
Increased sensitivity to anesthetic drugs (e.g. micovaronium, pancuronium)
Reduced beta-adrenoceptor function
Reduced sensitivity to the effect of verapamil on cardiac conduction
Reduced sensitivity to the chronotropic effect of isoprenaline
Greater inhibition of synthesis of vitamin K-dependent clotting factors 
by warfarin
aComprehensive information on this topic is available in recent reviews [34, 35]. CNS, central nervous system.
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the elderly, and strive to achieve those skills and insights 
typical of geriatricians.
Internists should be trained to use multidimensional 
evaluation tools that broadly explore clinical, nutritional, 
functional, cognitive, psychological, and socioeconomic 
domains, providing a global assessment of the needs of 
the elderly [94–100]. In this multidimensional process, 
critical assessment of the appropriateness of pharmaco-
logical treatments and polypharmacy-related problems 
should become a priority, considering the patient’s 
global prognosis, expected benefi t and time to attain 
benefi t of drug therapy, goals of care, and life expectancy 
[94, 95, 101–104]. Moreover, a more critical use of the 
available guidelines is needed, favoring those methods 
designed for tailoring clinical guidelines to the comor-
bidity profi le of individual patients as suggested by the 
‘payoff time’ model [100] or by clinical care models for 
patients with multimorbidity [30]. 
Another important goal is the periodic critical review 
of all the medications taken [39, 79, 95, 101]. This may 
help to reconsider which medications are still really 
needed and which could or should be discontinued. The 
importance of setting priorities and discontinuing drug 
therapies has been documented in different studies and 
is vital when a patient is followed by many different spe-
cialists, lives alone, takes many potentially inappropriate 
drugs, has poor adherence, and is approaching the end of 
life [102–108]. For many elderly people, when clinical 
and functional health deteriorates, the aggressiveness of 
drug therapies needs to be reconsidered and clinicians 
must accurately select diseases that truly merit priority 
for treatment with the corresponding drugs. Maintain-
ing an appropriate prescription in older patients is a 
dynamic process that requires periodic reassessment of 
the patient’s functional and cognitive status, disease pri-
orities, socioeconomic situations, living arrangements, 
formal or informal support, and life expectancy, with 
the aim to simplify and adjust drug therapy as needed 
[79, 102, 103, 106, 107]. Ample evidence supports the 
need to critically reassess medication appropriateness and 
discontinuation in elderly people [106–113]. In certain 
patient populations, discontinuing some drugs low-
ers the risk of inappropriateness, reducing adverse drug 
reactions and cost without jeopardizing clinical success.
How to review the appropriateness of drug 
prescription
During the last few decades, much effort has been 
directed to improving the quality of prescribing for 
elderly people, and several instruments and criteria 
have been developed by geriatricians or pharmacists 
[114–128]. Table 4 summarizes the most widely cited 
explicit and implicit criteria. Explicit criteria are 
doses of 12 different drugs at fi ve different times of the 
day, with a high risk not only of poor adherence but also 
of adverse reactions from drug–drug and drug–disease 
interactions [28]. Reliable data on patients aged 80 years 
or older are still not available for many diseases seen by 
the internists, and benchmark mortality endpoints are 
often of less concern for the elderly than quality-of-life 
issues.
Aging and frailty can also limit access to the con-
ventional processes of care [84, 86] and, as reviewed 
by Weiss [87], when frail older adults interact with the 
healthcare system, an incomplete or distorted under-
standing of frailty on the part of healthcare providers 
can lead to an inverse relationship between an indi-
vidual’s physiologic reserves and the level of demands 
placed on a person by the healthcare system. In con-
ditions of low physiologic reserve, increased demands 
can dissipate limited resources, leading to an amplifi -
cation of physiologic ineffi ciency. Hearing, visual and 
cognitive impairments can compromise medication 
compliance, and living alone and economic diffi cul-
ties also complicate the use of vital healthcare services 
and diagnostic procedures, and the implementation of 
healthy lifestyle recommendations. Although survival 
is still an important outcome for many elderly people, a 
recent study has shown that maintaining a good qual-
ity of life and independence was indicated as the most 
important health outcome by nearly 80% of 357 par-
ticipants [88]. So, internists must now include in their 
clinical practice health outcomes oriented towards a 
more comprehensive care of the different needs of the 
elderly, such as preventing the geriatric syndrome (e.g. 
falls, urinary incontinence, orthostatic hypotension, 
delirium, and depression), management of chronic 
pain, disability, and cognitive decline, with the aim 
of reducing rehospitalization and institutionalization 
[13, 84, 89–93].
How can internal medicine tackle the new 
challenges of an aging population? 
In general, the subspecialties of internal medicine still 
lack a systematic approach that incorporates age-related 
complexities into routine clinical decision-making. For 
the internist, the holistic and comprehensive approach 
for which she/he has been trained should, in principle, 
make it easier to tackle the challenges of multimorbidity. 
Nevertheless, the internist sometimes overlooks cogni-
tive decline, functional limitations, pain, and geriatric 
syndromes, which in elderly patients often infl uence 
decisions and priorities on healthcare. The internal 
medicine community must therefore become profi cient 
in the standards of care peculiar to the management of 
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usually drug- or disease-oriented and are established by 
expert consensus in order to draw up lists of medica-
tions that are contraindicated or should be avoided in 
elderly people or those with specifi c diseases [114–128]. 
Implicit criteria are mainly based on clinical judgment 
and are used to assess each prescribed drug with an 
individualized approach, in relation to a specifi c indi-
cation, effectiveness, dosage, adverse effects, and costs 
[122–124]. Each criterion has advantages and limita-
tions refl ecting its purpose, generalizability to different 
countries or elderly groups, updating regularity, crite-
ria used to measure appropriateness, presence or lack of 
information on failure to prescribe drugs indicated for 
treatment or prevention of specifi c diseases, and inclu-
sion or exclusion of the most frail and vulnerable people 
with multiple chronic diseases [126–128]. 
One problem is that clinicians experience diffi culties 
in applying these instruments in daily practice, because 
of lack of time, poor pharmacological knowledge, fear of 
discontinuing or substituting drugs prescribed by others, 
and scepticism toward the use of too sophisticated instru-
ments. Table 5 summarizes some of the most commonly 
encountered medication-related problems, their poten-
tial risks, examples of the medication, or drug classes 
most frequently involved, and questions that should be 
routinely used in order to critically assess and check the 
quality and appropriateness of drug prescription. 
Is a new clinical approach and paradigm of care 
needed by the internist?
The current paradigm of care for the elderly admitted to 
internal medicine wards is based on extrapolation from 
conventional evidence-based guidelines for each of the 
multiple diseases these patients often suffer. However, 
there is no evidence that the evidence-based therapeutic 
approach to a single disease is also applicable to multiple 
diseases and the corresponding use of multiple drugs, 
because there are simply no trials of polypharmacy in 
patients with multiple diseases (and admittedly they are 
diffi cult to plan). Not only is evidence-based knowledge 
on the effi cacy of polypharmacy lacking but also there 
is the question of assuring safety. It is therefore time for 
a new approach by the internist for the care of elderly 
people, based on a combination of problem-based and 
patient-oriented medicine, as summarized in Table 6 
and discussed below. 
Internists should improve their skills for a comprehensive a. 
evaluation of each patient, assessing not only clinical 
problems but also functional, cognitive, behavioral, and 
socioeconomic issues [95, 97, 98]. Some standardized 
tools developed by specialists in geriatric medicine, 
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Living [130], and the Mini-Mental State Examination 
[130] should facilitate the assessment phase. A 
comprehensive assessment of the patient soon after 
the admission has the advantage of providing clinicians 
with essential information to better plan the diagnostic 
and therapeutic approach during hospitalization, and to 
assess the discharge possibilities, reducing the length of 
hospital stay, and the risk of adverse events. 
Decisions on diagnostic tests and care should be taken b. 
according to each patient’s age, life expectancy, goals of 
therapies (curative or palliative), treatment target (e.g. 
treatment of acute illnesses, prevention of morbidity 
and mortality, life prolongation, maintenance of 
current functional or health state, and quality of life) 
and the expected time until benefi t is achieved [104]. 
Treatments for symptom relief (e.g. analgesics) or acute 
bacterial infections (e.g. antibiotics) usually need a short 
time to benefi t and can be prescribed to all patients. 
On the other hand, drugs for primary or secondary 
prevention of diseases, such as antihypertensive 
medications or statins, that require long-term dosing 
to obtain benefi t, should only be started in patients 
with an adequate life expectancy. Moreover, despite 
considerable uncertainty about the best use of cancer 
screening tests in older adults, there is the need for 
weighing quantitative information, such as the risk of 
cancer death and the likelihood of benefi t–risk ratio 
of the screening outcomes and individual patient’s 
values and preferences. A framework for individualized 
decision-making provides a helpful example of how 
there is a substantial variability in the likelihood of 
benefi t for patients of similar ages with varying life 
expectancy [105]. 
Care should be provided in accordance with best c. 
practice, and when possible should be evidence-based. 
However, when no such evidence is available, clinicians 
should identify some reliable and realistic targets for 
therapies, and then monitor the patient to assess target 
achievement or adverse drug events [24, 25, 28, 79]. 
Therefore, prescriptions should not be considered a 
single point in time of care, but a dynamic process in 
which the benefi ts and harms of drugs are continuously 
monitored, managed, and reassessed over time in a 
comprehensive longitudinal process. 
Another important goal is the critical assessment d. 
of drugs already prescribed at the time of hospital 
admission and of conservative prescribing at discharge. 
The internist should rigorously reconsider which 
medications are really needed and those that could be 
stopped. Reasons for priorities and discontinuation 
are well documented [103, 106–108]. To implement 
these processes in daily clinical practice, clinicians may 
choose to use some instruments (see Table 4), or keep 
in mind some simple suggestions: (1) critical assessment 
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of drug therapies should be comprehensive and include 
a review of medical history and physical examination; 
(2) all medications should be reviewed according to 
their indication, dosages, benefi t–risk profi le, expected 
time to benefi t, patient’s compliance, adverse drug 
reactions and risk of drug–drug or drug–disease 
interactions, functional and cognitive status, and effects 
on the quality of life; (3) potentially inappropriate 
drugs should be identifi ed and their discontinuation 
considered; (4) the plan of discontinuation should be 
defi ned and discussed with other clinicians (the general 
practitioner should be informed) and communicated to 
the patient and/or the caregiver; (5) the patient should 
be followed up after discontinuation for benefi cial or 
harmful effects. 
Discontinuation should be guided by a review of e. 
medication-related problems [38, 39, 46, 111] (see Table 
5) and the pharmacological characteristics of drugs to be 
stopped, in order to avoid adverse events related to drug 
withdrawal (e.g. agitation, anxiety, confusion, delirium, 
or insomnia after discontinuation of a benzodiazepine), 
exacerbation of the condition for which the drug was 
originally prescribed (e.g. worsening of palpitations after 
withdrawing digoxin for heart failure), or the appearance 
of new symptoms (e.g. anxiety, insomnia, hallucinations, 
or depression after discontinuation of baclofen). 
Discontinuation may also be appropriate when 
lifestyle changes and behavioral interventions are able 
to replace pharmacologic treatment. There is evidence 
that non-pharmacologic interventions are preferred as 
initial treatment for a range of diseases too commonly 
treated with drugs (e.g. diabetes, hypercholesterolemia, 
hypertension, arthritis, insomnia, depression, and back 
pain). Thus, internists should become more skilled and 
effective at recommending smoking cessation, diet 
changes, exercise, physical therapy, and psychotherapy 
when appropriate. 
To overcome the new challenges of the aging f. 
population, the internist cannot work in isolation, 
because team care is essential to provide high-quality 
care for patients with multiple chronic diseases 
and polypharmacy [132, 133]. Although clinicians 
are poorly trained to work in teams and are often 
reluctant to delegate parts of care involving other 
professionals (clinical pharmacologists, geriatric 
nurses, nutritionists, physical therapists, psychologists, 
Table 6 Proposals for a new clinical approach and paradigm of care in internal medicine. 
Proposal Approach/Paradigm
Emphasize and practice a 
combination of problem-based and 
patient-oriented medicine
Promote a global approach to clinical evaluation of elderly patients with multiple diseases and 
polypharmacy
Evaluate the overall effect of complexity and comorbidity not only as the sum of single 
diseases
Set priorities for clinical, functional, and cognitive problems
Identify realistic goals refl ecting age-related risks, standards of care, available guidelines, 
and patient’s health expectations 
Consider comorbidity, life expectancy, quality of life, and disability during the clinical 
assessment and the benefi t–risk evaluation for diagnostic and therapeutic choices
Incorporate end-of-life issues in the balance for routine care, and plan end-of-life care for 
patients with untreatable diseases
Incorporate patient’s preferences into care planning
Consider and screen for geriatric 
syndromes 
Screen for functional and cognitive impairment, chronic pain, depression, urinary incontinence, 
risk of falls that limit patient’s quality of life and increase disability, frailty, and mortality 
Incorporate in clinical practice some simple standardized geriatric tools such as Barthel Index, 
Activities of Daily Living Index (ADL), and Instrumental Activities of Daily Living Scale 
(IADL) for assessing disability, Mini-Mental State Examination (MMSE) test for cognitive 
function, and Geriatric Depression Scale (GDS) for depression 
Evaluate and manage pharmacological 
problems 
See Tables 2, 3, and 5 
Consider potentially treatable causes of disease, and seek to prevent rather than treat symptoms 
or advanced diseases
Implement electronic prescribing tools with decision support and instant feed-back on 
prescribing risk for drug interactions, prescribing errors or inappropriate drug use 
Promote and practice 
multidisciplinary and team care
Promote coordination and collaboration among all those caring for patients by discussing 
and sharing goals of care, monitoring and outcomes
Improve communication with primary care physicians, social workers and persons involved 
in the patient’s care
Educate patients Educate patients (or caregivers) to improve self (patient) care, lifestyle (diet, physical activity, 
smoking cessation), appropriate use of medications and health services (social support, home 
care, home monitoring)
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and social workers), a team approach should boost 
the effi cacy and comprehensiveness of the clinical 
evaluation and therapeutic choices.
Other important topics are coordination among g. 
clinicians and caregivers, and improvement in terms of 
communication of clinical and therapeutic decisions for 
the elderly [134, 135]. Thus, in the absence of electronic 
health records comprehensively covering the whole 
healthcare system and all the clinicians involved in the 
care of elderly people, a close relationship with the family, 
primary care physician and social workers is essential at 
hospital admission and discharge [136]. Coordination of 
care requires discussion, assessment of available resources, 
compromises and negotiations between all parties. Well-
coordinated information should be provided to the 
family, spouse, caregiver and all the persons involved 
in a patient’s care, without undermining the patient’s 
autonomy and right to make informed choices [137]. 
Communication and transparency between all h. 
providers of care and the health and social services 
are also essential for personalized healthcare choices 
[136, 138, 139]. Coordination and communication 
should improve the transfer of hospital care details 
across different hospitals, between hospital units, and 
at discharge when the patient goes home or to an 
institution. In these situations, reinforcing coordination 
and communication is essential to reduce patient’s 
stress, confusion, and agitation, and to improve such 
outcomes as long-term adherence to care, rates of 
re-hospitalization, and quality of life [138–140].
An important topic is the incorporation of end-of-life i. 
issues in the routine care [93]. Planning end-of-life care 
for patients with untreatable diseases is likely to help 
them to accept the inevitability of death as part of the 
human life cycle, relieve the feeling of isolation, reorient 
therapeutic choices away from treatments that may 
no longer be useful, and focus on less-aggressive and 
cost-effective alternative approaches, such as homecare, 
home–hospital, and hospice. 
What changes are needed in the training of 
internists and in research?
Training of new internists and clinical research are 
essential components in order to improve and imple-
ment any new strategy of evaluation and management 
of the complexity and frailty of elderly patients with 
multiple diseases and polypharmacy. Learned societies 
of internal medicine and postgraduate schools should 
emphasize all the aforementioned problems related to 
comorbidity and include these topics in the training of 
specialists and in continuing medical education for spe-
cialized internists.
Research is vital to establish the best strategies of care 
for elderly patients admitted to internal medicine wards. 
Registries of older patients, designed to collect data and 
information with the goal of studying their comorbidity, 
polypharmacy, and complexity of care should help us bet-
ter understand the global effects of therapies on clinical 
and functional outcomes. This evidence might serve as a 
practical basis for planning randomized controlled trials 
to assess how the different numbers and combination of 
drugs in different groups of patients, stratifi ed according 
to identifi ed disease clusters, affect mortality, disability, 
quality of life, and health or social care utilization. These 
studies should aim to compare the outcomes of various 
treatment regimens for those diseases that are more com-
mon in elderly populations and to assess the clinical effect 
and the adverse events of complex drug regimens in high 
prevalent clusters of diseases. A recently published article 
has analyzed the steps needed for enhancing the appli-
cability of comparative effectiveness research to patients 
with multiple chronic diseases [25].
Research should also study the clinical burden of 
drug–drug interactions associated with the complex 
regimens for older person exposed to many drugs at 
the same time. These studies should examine how these 
multiple drugs interact globally and infl uence the over-
all benefi t–risk profi le of healthcare. Finally, there is the 
need to rethink the approach currently used to produce 
guidelines. In spite of the lack of detailed evidence of 
the complexity of elderly people with multimorbidity 
and polypharmacy, an effort to include and discuss these 
topics should be made, collecting data from registries, 
observational studies, or qualitative research.
Conclusions
Modern health and social care now faces the growing 
challenges of rapidly aging populations as a result of the 
great advances made in public health, medical and phar-
macological research, and preventive medicine. Internal 
medicine and internists are called to play a primary role in 
promoting a new integrated, comprehensive approach to 
the care of elderly people that should incorporate the com-
plexity of age-related issues into routine clinical practice 
and decision-making. The internists of the third millen-
nium must extend their paradigm of care beyond their 
specialty and embrace a multisystem approach, taking 
account of age-related changes, functional and cognitive 
impairment, comorbidities, polypharmacy, psychological 
factors, socioeconomic factors, and personal preferences. 
This shift is essential for individualized care of older peo-
ple, for more rational and conservative drug prescribing, 
and to innovate evidence-based medicine with specifi c 
attention to clinical outcomes and patient satisfaction.
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Most importantly, the novel approach that the internist 
should develop in order to optimally provide health-
care to the elderly – for the many reasons set out in this 
article – is also governed by the global fi nancial crisis 
that is affecting the whole world. Because it appears 
inevitable that some degree of rationing of the ever 
more limited resources for healthcare will occur in the 
second decade of the third millennium, a more rational 
approach to the medical treatment of the elderly might 
not only help to reduce the cost of polypharmacy but 
could also save money in terms of less hospital admis-
sions for adverse effects.
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